All In Biotech

Drug Trial Radar · NCT06024239

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)

A Multiple Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Subjects, Subjects With Generalized Anxiety Disorder (GAD) and Subjects With Bipolar Disorder

Last checked: Nov 19, 2026Latest source record: Mar 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Aug 31, 2023

Primary completion

Mar 4, 2025

Study completion Mar 4, 2025

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Sep 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the pharmacokinetics, safety, and tolerability following multiple ascending oral doses of ABBV-932 or placebo in healthy adult participants, participants with Generalized Anxiety Disorder (GAD), and participants with bipolar disorder (BPD).

Conditions

  • Healthy Volunteers
  • Generalized Anxiety Disorder (GAD)
  • Bipolar Disorder (BPD)

Interventions

  • ABBV-932Drug

    Capsule; oral

  • Placebo for ABBV-932Drug

    Capsule; oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax)Time frame: Up to Day 28
  2. Time to Cmax (Tmax)Time frame: Up to Day 28
  3. Plasma Concentrations at Pre-dose or at the End of a Dosing Interval (Ctrough)Time frame: Up to Day 28
  4. Area under the Plasma Concentration-time Curve from Time Zero to the End of the Dosing Interval (AUCtau)Time frame: Up to Day 28
  5. Number of Participants with Adverse Events (AEs)Time frame: Baseline to Day 129

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Collaborative Neuroscience Research CNS /ID# 260270

    Los Alamitos, California

  • Acpru /Id# 255945

    Grayslake, Illinois

  • Hassman Research Institute Marlton Site /ID# 260271

    Marlton, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.